Genexine has been granted a patent for a method to treat HPV-induced cervical tumors by administering a combination of an HPV-specific fusion protein and an immunomodulatory agent. The method aims to enhance treatment efficacy compared to individual therapies. GlobalData’s report on Genexine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Genexine Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genexine, Peptide pharmacophores was a key innovation area identified from patents. Genexine's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of hpv-induced cancer using hpv vaccine and checkpoint inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Genexine Inc

A recently granted patent (Publication Number: US11883479B2) outlines a method for treating human papillomavirus (HPV)-induced cancer by administering an HPV vaccine and a checkpoint inhibitor agent to the subject simultaneously. The combination treatment aims to generate a therapeutic effect greater than either treatment alone when used as monotherapy. The HPV vaccine, which may include a specific nucleic acid construct, is administered multiple times at a specified dose, while the checkpoint inhibitor agent, such as a PD-1/PD-L1 inhibitor, is given at a different dose range and administration route.

Furthermore, the patent details the specific dosages, administration schedules, and types of HPV-induced cancers, such as cervical cancer, that can be treated using this method. The combination therapy is designed for subjects with metastatic, recurrent, or advanced cancer who have undergone or are undergoing anti-cancer treatment. The patent also specifies the use of certain checkpoint inhibitors like pembrolizumab and various HPV strains, such as HPV 16 and HPV 18, in conjunction with the HPV vaccine. Overall, the method described in the patent aims to enhance the therapeutic outcomes for HPV-induced cancer patients by combining two distinct treatments within a common time period.

To know more about GlobalData’s detailed insights on Genexine, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies